Replies to post #7628 on Avid Bioservices Inc (CDMO)

[xzoneclone]

That, would be real nice however,

I see it exactly opposite.....

They would test the 6mg dosing to see if there were added benefit or not...If there is, chances are they would take it to a higher level....

A infusion is an infusion....1, 3, 6mg

Takes the same amount of time....

Though concur, less drug...
You might be right, Perhaps they are under-stating their goals and data, and are gonna drop the hydrogen bomb instead of the atomic one......

That indeed would be novel concept for Peregrine.....

[terrygd]

And Oncolym has been sitting on the shelf for how many years? Not one licensee interested? This was long before Bavi was the new game in town.

Long-term complete responses after (131)I-tositumomab therapy for relapsed or refractory indolent non-Hodgkin's lymphoma. (Source: Br J Cancer.) Full Citation:Br J Cancer. 2006 Jun 19;94(12):1770-6. Epub 2006 May 9.

Publisher's Abstract
Buchegger F, Antonescu C, Delaloye AB, Helg C, Kovacsovics T, Kosinski M, Mach JP, Ketterer N.

[1] 1Service of Nuclear Medicine, University Hospital of Lausanne, CH-1011 Lausanne, Switzerland [2] 2Service of Nuclear Medicine, University Hospital of Geneva, CH-1211 Geneva 14, Switzerland.

We present the long-term results of 18 chemotherapy relapsed indolent (N=12) or transformed (N=6) NHL patients of a phase II anti-CD20 (131)I-tositumomab (Bexxar((R))) therapy study. The biphasic therapy included two injections of 450 mg unlabelled antibody combined with (131)I-tositumomab once as dosimetric and once as therapeutic activity delivering 75 or 65 cGy whole-body radiation dose to patients with normal or reduced platelet counts, respectively. Two patients were not treated due to disease progression during dosimetry. The overall response rate was 81% in the 16 patients treated, including 50% CR/CRu and 31% PR. Median progression free survival of the 16 patients was 22.5 months. Median overall survival has not been reached after a median observation of 48 months. Median PFS of complete responders (CR/CRu) has not been reached and will be greater than 51 months. Short-term side effects were mainly haematological and transient. Among the relevant long-term side effects, one patient previously treated with CHOP chemotherapy died from secondary myelodysplasia. Four patients developed HAMA. In conclusion, (131)I-tositumomab RIT demonstrated durable responses especially in those patients who achieved a complete response. Six of eight CR/CRu are ongoing after 46-70 months.British Journal of Cancer (2006) 94, 1770-1776. doi:10.1038/sj.bjc.6603166 www.bjcancer.com Published online 9 May 2006.

[technicalwin]

CS, could not agree more on the prediction. I base my agreement on Bavi's MOA and a working immune system. It is interesting that MER was on the CC. If they are doing their DD so they can get in early, this fall should be very interesting. MD Anderson is also interesting for moving Bavi to the next level even if we have no details on the subject. Hopefully the P1b results will slow down the manipulation of this stock. TW

[ThomasS]

You people are out of your minds making predictions like that!
Totally unproductive guesses that hurt uninformed investors.